



IFW

CERTIFICATE OF MAILING
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

October 5, 2004
Date


Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Rolf A. Brekken

Serial No.: 10/738,404

Filing Date: December 17, 2003

For: ANTI-VEGF ANTIBODY PRODRUG
METHODS (As Amended)

Group Art Unit: 1642

Examiner: Yaen, C.

Atty. Dkt. No.: 3999.002587

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that the present Supplemental Information Disclosure Statement be entered and the documents listed on the enclosed Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees should be due in connection herewith. Even if an Official Action had been issued in the last few days, no fees would be required in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed in the accompanying Form PTO-1449 were not cited in a communication from a foreign patent office in a counterpart foreign application. The listed documents were identified during research conducted by legal representatives of the licensee of the present application in connection with the licensee's Opposition against a European patent to another. The research was initiated on about July 20, 2004, and was completed on August 20, 2004, and the present statement is being filed within three months of the initiation of the research.

No fees should be due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/3999.002587.

Respectfully submitted,
Williams, Morgan & Amerson, P.C.
Customer No. 23720



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

10333 Richmond, Suite 1100
Houston, Texas, 77042
(713) 934-4079

Date: October 5, 2004

Form PTO-1449 (modified)

Atty. Docket No.

3999.002587

Serial No.

10/738,404

List of Patents and Publications for Applicant's

Applicant

Thorpe and Brekken

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

December 17, 2003

Group:

1642

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page 1

Other Art

See Pages 1-5

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B19	EP 0 484 401 B1	September 11, 1996				
	B20	WO 91/02058	February 21, 1991				
	B21	WO 90/13649	November 15, 1990				

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C99	Aiello, "Suppression of Retinal Neovascularization In Vivo by Inhibition of Vascular Endothelial Growth Factor (VEGF) Using Soluble VEGF-Receptor Chimeric Proteins," <i>Proc. Natl. Acad. USA</i> , 92:10457-10461, 1995.
	C100	Alvarez <i>et al.</i> , "Localization of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor in Human Glial Neoplasms," <i>Modern Pathology</i> , 5(3):303-307, 1992.
	C101	Auerbach, "Vascular Endothelial Cell Differentiation: Organ-Specificity and Selective Affinities as the Basis for Developing Anti-Cancer Strategies," <i>Int. J. Radiat. Biol.</i> , 60(1/2):1-10, 1991.
	C102	Baird <i>et al.</i> , "Immunoreactive Fibroblast Growth Factor (FGF) in a Transplantable Chondrosarcoma: Inhibition of Tumor Growth by Antibodies to FGF," <i>J. Cell. Biochem.</i> , 36:79-85, 1986.
	C103	Berse <i>et al.</i> , "Vascular Permeability Factor (Vascular Endothelial Growth Factor) Gene is Expressed Differentially in Normal Tissues, Macrophages, and Tumors," <i>Molecular Biology Cell</i> , 3:211-220, 1992.
	C104	Berse <i>et al.</i> , "Vascular Permeability Factor Vascular Endothelial Cell Growth Factor Expression in Normal Tissues and in Tumors," <i>J. Cell Biol.</i> , 115(3 part 2):421a, Abstract No. 2443, 1991.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. 3999.002587	Serial No. 10/738,404
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: December 17, 2003	Group: 1642
U.S. Patent Documents See Page	Foreign Patent Documents See Page 1	Other Art See Pages 1-5	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C105	Broadley <i>et al.</i> , "Monospecific Antibodies Implicate Basic Fibroblast Growth Factor in Normal Wound Repair," <i>Lab. Invest.</i> , 61(5):571-575, 1989.
	C106	Brock <i>et al.</i> , "Tumor-Secreted Vascular Permeability Factor Increases Cytosolic Ca ²⁺ and von Willebrand Factor Release in Human Endothelial Cells," <i>Am. J. Path.</i> , 138(1):213-221, 1991.
	C107	Brown <i>et al.</i> , "Leaky Vessels, Fibrin Deposition, and Fibrosis: A Sequence of Events Common to Solid Tumors and to Many Types of Disease," <i>Am. Rev. Respir. Dis.</i> , 140:1104-1107, 1989.
	C109	Clauss <i>et al.</i> , "Vascular Permeability Factor: A Tumor-Derived Polypeptide that Induces Endothelial Cell and Monocyte Procoagulant Activity, and Promotes Monocyte Migration," <i>J. Exp. Med.</i> , 172:1535-1545, 1990.
	C109	Conn <i>et al.</i> , "Purification of a Glycoprotein Vascular Endothelial Cell Mitogen from a Rat Glioma-Derived Cell Line," <i>Proc. Nat. Acad. Sci. USA</i> , 87:1323-1327, 1990.
	C110	Conn <i>et al.</i> , "Amino Acid and cDNA Sequences of a Vascular Endothelial Cell Mitogen that is Homologous to Platelet-Derived Growth Factor," <i>Proc. Natl. Acad. Sci. USA</i> , 87:2628-2632, 1990.
	C111	Connolly, "Vascular Permeability Factor: A Unique Regulator of Blood Vessel Function," <i>J. Cell Biochem.</i> , 47:219-223, 1991.
	C112	Connolly, "Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis," <i>J. Clin. Invest.</i> , 84:1470-1478, 1989.
	C113	Denekamp, "Vasculature as a Target for Tumour Therapy," <i>Prog. Appl. Microcirc.</i> , 4:28-38, 1984.
	C114	Dennis and Rifkin, "Studies on the Role of Basic Fibroblast Growth Factor <i>In Vivo</i> : Inability of Neutralizing Antibodies to Block Tumor Growth," <i>J. Cell. Physiol.</i> , 144:84-98, 1990.
	C115	Dvorak <i>et al.</i> , "Vascular Permeability Factor, Fibrin, and the Pathogenesis of Tumor Stroma Formation," <i>Ann. N.Y. Acad. Sci.</i> , 667:101-111, 1992.
	C116	Dvorak, "Leaky Tumor Vessels: Consequences for Tumor Stroma Generation and for Solid Tumor Therapy," <i>Progress in Clinical and Biological Research</i> , 354a: 317-330, 1990.
	C117	Dvorak, "Tumors: Wounds That Do Not Heal," <i>New Eng. J. Med.</i> , 315(26):1650-1659, 1986.
	C118	Dvorak <i>et al.</i> , "Regulation of Extravascular Coagulation by Microvascular Permeability," <i>Science</i> , 227:1059-1061, 1985.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified) OCT 07 2004		Atty. Docket No. 3999.002587	Serial No. 10/738,404
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: December 17, 2003	Group: 1642
U.S. Patent Documents See Page	Foreign Patent Documents See Page 1	Other Art See Pages 1-5	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C119	Dvorak <i>et al.</i> , "Fibrin as a Component of the Tumor Stroma: Origins and Biological Significance," <i>Cancer Metastasis Reviews</i> , 2:41-73, 1983.
	C120	Ferrara <i>et al.</i> , "Expression of Vascular Endothelial Growth Factor Does Not Promote Transformation but Confers a Growth Advantage <i>In Vivo</i> to Chinese Hamster Ovary Cells," <i>J. Clin. Invest.</i> , 91:160-170, 1993.
	C121	Ferrara <i>et al.</i> , "The Vascular Endothelial Growth Factor Family of Polypeptides," <i>J. Cell. Biochem.</i> , 47:211-218, 1991.
	C122	Ferrara and Henzel, "Pituitary Follicular Cells Secrete A Novel Heparin Binding Growth Factor Specific for Vascular Endothelial Cells." <i>Biochem. Biophys. Res. Comm.</i> , 161(2):851-858, 1989.
	C123	Ferrara <i>et al.</i> , "Molecular Characterization and Distribution of Vascular Endothelial Growth Factor," <i>J. Cell Biochem. Supp.</i> , 151(part F):p211, 1991, Abstract No. CF016.
	C124	Folkman and Ingber, "Inhibition of Angiogenesis," <i>Seminars in Cancer Biology</i> , 3:89-96, 1992.
	C125	Folkman and Shing, "Angiogenesis," <i>J. Biol. Chem.</i> , 267(16):10931-10934, 1992.
	C126	Folkman <i>et al.</i> , "Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia," <i>Nature</i> , 339:58-61, 1989.
	C127	Folkman, "What is the Evidence that Tumors are Angiogenesis Dependent?," <i>J. Natl. Cancer Inst.</i> , 82(1):4-6, 1990.
	C129	Folkman and Klagsbrun, "Angiogenic Factors," <i>Science</i> , 235:442-447, 1987.
	C129	Gospodarowicz <i>et al.</i> , "Isolation and Characterization of a Vascular Endothelial Cell Mitogen Produced by Pituitary-Derived Folliculo Stellate Cells," <i>Proc. Natl. Acad. Sci.</i> , 86:7311-7315, 1989.
	C130	Greenblatt and Shubi, "Tumor Angiogenesis: Transfilter Diffusion Studies in the Hamster by the Transparent Chamber Technique," <i>J. Natl. Cancer Inst.</i> , 41:111-124, 1968.
	C131	Houck <i>et al.</i> , "The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA," <i>Molecular Endocrinology</i> , 5:1806-1814, 1991.
	C132	Jain, "Haemodynamic and Transport Barriers to the Treatment of Solid Tumours," <i>Int. J. Radiat. Biol.</i> , 60(1/2):85-100, 1991.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

3999.002587

Serial No.

10/738,404

Applicant

Thorpe and Brekken

Filing Date:

December 17, 2003

Group:

1642

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page 1

Other Art

See Pages 1-5

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C133	Jakeman <i>et al.</i> , "Binding Sites for Vascular Endothelial Growth Factor are Localized on Endothelial Cells in Adult Rat Tissues," <i>J. Clin. Invest.</i> , 89:244-253, 1992.
	C134	Keck <i>et al.</i> , "Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF," <i>Science</i> , 246:1309-1312, 1989.
	C135	Kerbel, "Inhibition of Tumor Angiogenesis as a Strategy to Circumvent Acquired Resistance to Anti-Cancer Therapeutic Agents," <i>BioEssays</i> , 13(1):31-36, 1991.
	C136	Leung <i>et al.</i> , "Cloning, Expression During Development, and Evidence for release of a Trophic Factor for Ciliary Ganglion Neurons," <i>Neuron</i> , 8:1045-1053, 1992.
	C137	Leung <i>et al.</i> , "Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen," <i>Science</i> , 246:1306-1308, 1989.
	C138	Li <i>et al.</i> , "Monoclonal Antibodies to Recombinant Human Vascular Endothelial Growth Factor (rHuVEGF)," <i>J. Cell. Biochem.</i> , Supp. 15F:251, Abstract CF417, 1991.
	C139	Pepper <i>et al.</i> , "Potent Synergism Between Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in the Induction of Angiogenesis <i>In Vitro</i> " <i>Biochem. Biophys. Res. Comm.</i> , 189(2):824-831, 1992.
	C140	Plate, "Vascular Endothelial Growth Factor is a Potential Tumour Angiogenesis Factor in Human Gliomas <i>In vivo</i> ," <i>Nature</i> , 359:845-848, 1992.
	C141	Plouet <i>et al.</i> , "Isolation and Characterization of a Newly Identified Endothelial cell Mitogen Produced by AtT-20 Cells," <i>EMBO</i> , 8(12):3801-3806, 1989.
	C142	Roberts and Palade, "Increased Microvascular Permeability and Endothelial Fenestration Induced by Vascular Endothelial Growth Factor," <i>J. Cell Sci.</i> , 108:2369-2379, 1995.
	C143	Senger <i>et al.</i> , "A Highly Conserved Vascular Permeability Factor Secreted by a Variety of Human and Rodent Tumor Cell Lines," <i>Cancer Research</i> , 46:5629-5632, 1986.
	C144	Senger <i>et al.</i> , "Purification and NH ₂ -Terminal Amino Acid Sequence of Guinea Pig Tumor-Secreted Vascular Permeability Factor," <i>Cancer Research</i> , 50:1774-1778, 1990.
	C145	Shweiki <i>et al.</i> , "Vascular Endothelial Growth Factor Induced by Hypoxia May Mediate Hypoxia-Initiated Angiogenesis," <i>Nature</i> , 359:843-845, 1992.
	C146	Sioussat <i>et al.</i> , "Anti-Peptide Antibodies to Vascular Permeability Factor," <i>J. Cell Biol.</i> , 115(3 part 2):p264A, Abstract No. 1528, 1991.

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 3999.002587	Serial No. 10/738,404
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Thorpe and Brekken	
		Filing Date: December 17, 2003	Group: 1642
U.S. Patent Documents See Page	Foreign Patent Documents See Page 1	Other Art See Pages 1-5	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C147	Tischer <i>et al.</i> , "Vascular Endothelial Growth Factor: A New Member of the Platelet-Derived Growth Factor Gene Family," <i>Biochem. Biophys Res. Comm.</i> , 165(3):1198-1206, 1989.
	C148	Van Brugen <i>et al.</i> , "VEGF Antagonism Reduces Edema Formation and Tissue Damage After Ischemia/Reperfusion Injury in the Mouse Brain," <i>J. Clin. Invest.</i> , 104(11):1613-1620, 1999.
	C149	Weidner, "Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma," <i>New. Eng. J. Med.</i> , 324(1):1-7, 1991.
	C150	Yeo <i>et al.</i> , "Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Guinea Pig and Human Tumor and Inflammatory Effusions," <i>Cancer Research</i> , 53:2912-2918, 1993.
	C151	Yeo <i>et al.</i> , "Development of Time-Resolved Immunofluorometric Assay of Vascular Permeability," <i>Clin. Chem.</i> , 38(1):71-75, 1992.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.